If the data for DIPG and GBM puts the drug on a track for NDA's then would you want; 1: be diluted again to get a team that can't get timelines 8 weeks out correct file a PRV NDA? or 2) Accept a takeover from an appropriately funded AND staffed Pharma with potential 'BioBuck' trailing milestone payments?
There is enough data on PI3K potential and good safety data for paxalisib that positive data in the next few months would see the Kazia board and management team being used in MBA courses on what not to do in the Pharma space.
Hold on, data will elevate the drug and we will get taken over.
KZA Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
